iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.I am Gen Alpha. I have more than 14 years of investment experience, and an MBA in Finance. I focus on stocks that are more defensive in nature, with a medium ...

Core Viewpoint - Abbott Laboratories' stock price pullback in January 2026 is seen as an overreaction driven by market sentiment rather than fundamental weaknesses, making the stock attractive for buying [2][4]. Financial Performance - Abbott reported Q4 revenue of $11.46 billion, reflecting a 4.5% increase year-over-year, with adjusted earnings per share (EPS) growing by 12%, slightly above consensus expectations [5]. - Despite some metrics falling short of market expectations, the company demonstrated solid sales growth and improved margins, indicating a strong operational performance [5][7]. Segment Analysis - The company's diversified healthcare portfolio showed strength, with Established Pharmaceuticals growing by 9% and Med Tech by 12.3%, while the Nutrition and Diagnostic segments faced declines, particularly a nearly 9% drop in Nutrition [6]. - The growth in the pharma segment was driven by generics and emerging markets, showcasing the resilience of Abbott's product offerings [6]. Margin and Earnings Outlook - Although margins fell short of analyst forecasts, they were supported by a favorable product mix, strength in Med Tech, and operational improvements, with expectations for continued earnings growth of 10% in 2026 [7]. - The company anticipates that earnings growth will outpace revenue growth, which is crucial for sustaining capital returns [7]. Capital Returns and Dividend Policy - Abbott is recognized as a Dividend King, having increased its dividend payout for over 50 years, with a current yield of approximately 2.5% [8]. - The company maintains a payout ratio of less than 50% of consensus earnings forecasts, allowing for share buybacks and reinforcing its capital return strategy [8].

Core Viewpoint - Abbott Laboratories (ABT), known as a Dividend King, experienced a decline in stock price following a mixed Q4 earnings report, indicating resilience but also facing headwinds in certain segments [1] Financial Performance - The Q4 earnings report was mixed, suggesting that while the company shows resilience, there are negative impacts from challenges in some segments [1] Market Reaction - The stock price drop reflects investor sentiment in response to the earnings report, highlighting the market's reaction to the company's performance [1]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Score identifies attractive stocks using financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors seeking undervalued opportunities [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing metrics like weekly price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.9% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Stock to Watch: Abbott (ABT) - Abbott, rated 2 (Buy) on the Zacks Rank, has a VGM Score of B and a Value Style Score of B, with a forward P/E ratio of 19.16, indicating attractive valuation [11] - Recent upward revision of earnings estimates for fiscal 2026 has increased the Zacks Consensus Estimate to $5.67 per share, with an average earnings surprise of +0.7% [12]

Group 1 - Worldwide Nutrition sales decreased by 8.9% on a reported basis and 9.1% on an organic basis in the fourth quarter [1] - The results in the quarter were influenced by lower sales volumes compared to the prior year and new strategic price actions aimed at increasing future volume growth [1] - Abbott (ABT) anticipates boosting volume growth with the launch of several new products in 2026 [1]

Core Insights - Abbott Laboratories reported Q4 2025 sales of $11.46 billion, a 4.4% increase year-over-year, but fell short of analyst projections by approximately 3% [2] - Adjusted EPS for the quarter was $1.50, meeting expectations, while total annual adjusted EPS reached $5.15, indicating a 10% growth [2] Financial Performance - Organic sales growth decreased to 3% during the quarter due to reduced demand in some areas [4] - Adjusted gross margin increased by 20 basis points to 57.1%, and operating margin expanded by 150 basis points to 25.8%, reflecting effective cost management [4] - Guidance for 2026 projects organic sales growth of 6.5%-7.5% and an adjusted EPS around $5.68 at the midpoint, aligning with consensus expectations [6] Valuation Dynamics - Abbott is currently priced at around $109 per share, trading at 21 times its trailing adjusted EPS of $5.15, down from a three-year average P/E of 24 times [6][7] - The forward P/E based on guidance is 19 times, indicating potential stability, but slowdowns in Nutrition and uncertainties regarding acquisitions limit optimism [7] Segment Performance - Medical Devices segment showed strong demand, particularly in structural heart and neuromodulation, with Freestyle Libre contributing significantly to organic growth [10] - Diagnostics revenue is normalizing post-COVID, with the Exact Sciences acquisition valued at up to $23 billion expected to enhance this sector [10] - Nutrition sales declined due to market dynamics, raising concerns about future growth in this segment [10] Future Catalysts and Risks - Potential upside for Abbott depends on realizing synergies from Exact Sciences, stabilization in Nutrition, and successful execution in high-growth devices [8] - Downside risks include persistent weakness in Nutrition, regulatory challenges with the Exact Sciences acquisition, and overall caution in medtech spending [9]

Core Viewpoint - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey, aiming for financial independence through investments [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since around 2009 [1]. - The blog "Kody's Dividends" was launched in July 2018 to document the author's financial independence journey through dividend growth investing [1]. - The author credits the blog for introducing them to the Seeking Alpha community as an analyst [1].

Core Insights - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey towards financial independence [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since 2009 [1]. - The blog "Kody's Dividends" was launched in July 2018 to share insights and experiences related to dividend growth investing [1]. - The author credits the blog for introducing them to the Seeking Alpha community as an analyst [1].

Core Viewpoint - Abbott Healthcare, an Indian drugmaker, is under investigation for the alleged misuse of its codeine-based cough syrup, which is known to be prone to abuse by addicts [1] Group 1: Company Overview - Abbott Healthcare's supply chain is currently being scrutinized as part of a broader investigation [1] Group 2: Industry Context - The investigation highlights concerns regarding the potential abuse of codeine-based medications within the pharmaceutical industry [1]

Group 1 - Sanhua Intelligent Control (02050) saw a decline of over 3.4% after announcing a share reduction plan involving the actual controller and several directors, with a total of up to approximately 10.2 million A-shares to be sold between February 24, 2026, and May 23, 2026 [1] - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60%, nearly erasing gains since October 2022, following stock movements involving major shareholders [1] - Zhongwei New Materials (02579) increased by over 5% as the company announced securing 5-6 billion wet tons of nickel ore resources and establishing four nickel raw material industrial bases in Indonesia [1] Group 2 - InnoCare Pharma (03696) rose over 6%, reaching a new high of 62.9 HKD, after receiving FDA approval for its oral NLRP3 inhibitor ISM8969 for Parkinson's disease treatment [2] - Solar stocks surged, with Kaisa New Energy (01108) up 17.85% and other companies like Fuyao Glass (06865) and Xinyi Solar (00968) also showing significant gains, driven by a report indicating a new phase in commercial space deployment [2] - Jiangnan Buyi (03306) fell nearly 7% after announcing a placement of 14.535 million shares at a discount to the market price [2] Group 3 - Lithium stocks rose, with Ganfeng Lithium (01772) up 5.22% and Tianqi Lithium (09696) up 2.88%, following a report of a significant increase in lithium carbonate contract prices [3] - Rongchang Bio (09995) increased nearly 2% after UBS expressed a positive outlook on its collaboration with AbbVie, which includes substantial milestone payments [4] - DCH Holdings (00179) fell nearly 7% as it reported a slight decline in revenue for the nine months ending December 31, 2025 [4] Group 4 - Gold stocks rebounded, with Chifeng Jilong Gold Mining (06693) up 6.99% and others also showing gains, as spot gold prices reached a new high of over $4,960 per ounce [4] - Bitgo Holdings (BTGO.US) debuted on the US stock market, rising 2.72% as a leading cryptocurrency custody provider [5] - Rare earth stocks surged, with USA Rare Earth (USAR.US) up 17.49% after announcing partnerships to advance its Round Top project [5] Group 5 - The Nasdaq Golden Dragon China Index opened up 1.6%, with major Chinese stocks like Li Auto (LI.US) and Alibaba (BABA.US) showing gains, supported by comments from the People's Bank of China regarding potential monetary easing [6] - Abbott (ABT.US) fell 10.04% after reporting lower-than-expected sales for Q4 2025, despite a year-over-year increase in adjusted EPS [7] - Alibaba (BABA.US) rose 5.05% as it plans to list its semiconductor division, benefiting from investor interest in competing with Nvidia [7]